You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 18, 2025

Details for Patent: 8,252,839


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,252,839 protect, and when does it expire?

Patent 8,252,839 protects ORENITRAM and is included in one NDA.

This patent has nineteen patent family members in seven countries.

Summary for Patent: 8,252,839
Title:Compounds and methods for delivery of prostacyclin analogs
Abstract: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula. ##STR00001##
Inventor(s): Phares; Ken (Chapel Hill, NC), Mottola; David (Cary, NC)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:12/078,955
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,252,839
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;
Patent landscape, scope, and claims:

United States Patent 8,252,839: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction to Patent 8,252,839

Patent Overview

United States Patent 8,252,839, titled "Compounds and methods for delivery of prostacyclin analogs," was granted on September 4, 2012. This patent pertains to the development and use of prostacyclin analogs for promoting vasodilation, inhibiting platelet aggregation, and treating conditions such as pulmonary hypertension[4].

Scope of the Patent

Background and Objectives

The invention focuses on prostacyclin analogs, which are synthetic compounds designed to mimic the biological activity of natural prostacyclin. These analogs are crucial for their therapeutic potential in promoting vasodilation and inhibiting platelet aggregation, thereby reducing the risk of thrombosis[4].

Claims and Innovations

Claims Analysis

The patent includes several key claims related to the composition and method of delivery for these prostacyclin analogs. Specifically:

  • Claim 1: A pharmaceutical composition comprising a prostacyclin analog, such as treprostinil, in a solution or mixture[4].
  • Claim 2: A method for promoting vasodilation and inhibiting platelet aggregation using a prostacyclin analog[4].
  • Claim 3: A dosage form, such as a capsule or tablet, containing a prostacyclin analog for therapeutic use[4].

Patent Landscape

Patent Family and Prior Art

The patent family for 8,252,839 includes related applications filed at various international patent offices. The Global Dossier service provided by the USPTO allows users to access the file histories of these related applications, including classification and citation data[1].

Legal Status and Expiration Date

Legal Status and Expiration Date

The legal status of Patent 8,252,839 is active, with an expiration date in May 2024. This information is crucial for pharmaceutical companies planning to develop or use these compounds in their products[4].

Impact on Pharmaceutical Industry

Impact on Pharmaceutical Industry

This patent has significant implications for the pharmaceutical industry, particularly in the development of treatments for pulmonary hypertension and other cardiovascular conditions. The use of prostacyclin analogs as described in this patent has been listed in the FDA Orange Book, indicating its relevance to drug development and regulatory compliance[5].

Search Resources for Patent Analysis

Search Resources for Patent Analysis

For detailed analysis of patents like 8,252,839, various search resources are available:

  • USPTO Public Search Facility: Provides access to patent and trademark information in various formats, including online, microfilm, and print[1].
  • Global Dossier: Offers a single portal for accessing file histories of related applications from participating IP Offices[1].
  • Patent Assignment Search: Allows users to search for patent assignments and changes in ownership[1].

Conclusion

In conclusion, United States Patent 8,252,839 is a critical document in the field of pharmaceuticals, particularly in the development of prostacyclin analogs for therapeutic use. Understanding the scope and claims of this patent is essential for pharmaceutical companies aiming to innovate within this therapeutic area.

Key Takeaways

  1. Therapeutic Application: The patent focuses on the therapeutic use of prostacyclin analogs for promoting vasodilation and inhibiting platelet aggregation.
  2. Composition Claims: The patent includes specific claims related to the composition of these analogs, including their formulation in solutions or mixtures.
  3. Dosage Forms: The patent describes various dosage forms such as capsules and tablets for therapeutic use.
  4. Legal Status: The patent is active with an expiration date in May 2024.
  5. Regulatory Compliance: The listing in the FDA Orange Book indicates its relevance to drug development and regulatory compliance.

FAQs

Q1: What is the primary focus of Patent 8,252,839? A1: The primary focus is on the development and therapeutic use of prostacyclin analogs for promoting vasodilation and inhibiting platelet aggregation.

Q2: What are some specific claims included in this patent? A2: Specific claims include the composition of prostacyclin analogs in solutions or mixtures, methods for promoting vasodilation, and dosage forms such as capsules and tablets.

Q3: How does this patent impact the pharmaceutical industry? A3: This patent has significant implications for the pharmaceutical industry, particularly in the development of treatments for pulmonary hypertension and other cardiovascular conditions.

Q4: What search resources are available for analyzing this patent? A4: Available search resources include the USPTO Public Search Facility, Global Dossier, and Patent Assignment Search.

Q5: What is the legal status of this patent? A5: The legal status of Patent 8,252,839 is active with an expiration date in May 2024.


Cited Information:

  1. USPTO Patent Search Tools: https://www.uspto.gov/patents/search
  2. Global Dossier: https://www.uspto.gov/patents/search
  3. Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. US Patent 8,252,839: https://patents.google.com/patent/US8252839B2/en
  5. PharmaCompass - US Patent 8252839: https://www.pharmacompass.com/us-patent-8252839

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,252,839

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-001 Dec 20, 2013 RX Yes No 8,252,839 ⤷  Subscribe Y ⤷  Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-002 Dec 20, 2013 RX Yes No 8,252,839 ⤷  Subscribe Y ⤷  Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-003 Dec 20, 2013 RX Yes Yes 8,252,839 ⤷  Subscribe Y ⤷  Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-004 Dec 20, 2013 RX Yes No 8,252,839 ⤷  Subscribe Y ⤷  Subscribe
United Therap ORENITRAM treprostinil diolamine TABLET, EXTENDED RELEASE;ORAL 203496-005 Oct 7, 2016 RX Yes No 8,252,839 ⤷  Subscribe Y ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 1 to 5 of 5 entries

International Family Members for US Patent 8,252,839

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Canada 2526534 ⤷  Subscribe
Canada 2736406 ⤷  Subscribe
Canada 2851309 ⤷  Subscribe
Canada 2959852 ⤷  Subscribe
China 100558351 ⤷  Subscribe
China 101265226 ⤷  Subscribe
China 101780092 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 7 of 7 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.